| 摘要 |
Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti- CD20 antibody, preferably RITUXAN.RTM. and a radiolabeled anti-CD22 antibody , preferably an 90Y labeled humanized anti-CD22 antibody, is described. These therapeutic regimens provide for enhanced depletion of B cells, and therefor e reduce the risk in B cell malignancy treatment of relapse associated with RITUXAN.RTM. and, moreover, provide for prolonged immunosuppression of B-cel l immune responses, especially in the context of autoimmune diseases and transplant.
|
